Quantcast

Latest Genetic disorders Stories

2012-06-22 11:52:36

'A Molecular Bandage for Diseased Muscle' appears today in prestigious Science publication Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy in an article published this week in Science Translational Medicine. "This is a focus article in which we summarize the impact of MG53 protein therapy as a treatment option and discuss the...

2012-06-21 23:03:15

Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. Columbia, SC (PRWEB) June 21, 2012 BDI Pharma, Inc. (BDI), the nation´s fastest growing national distributor of biotech therapies, after finishing the previous calendar year with a record level of distribution in anti-hemophilic factor (AHF), announced today that through the first five (5) months of 2012, the company´s distribution is tracking...

2012-06-21 06:19:46

(Ivanhoe Newswire) — More than 15,000 Americans have Huntington´s disease, a fatal condition marked by uncontrolled movements and cognitive and psychiatric problems. Currently, there are no available treatments to alter the effects of Huntington´s disease, but a new study brings researchers one step closer to finding one. A new gene-silencing strategy can reverse core symptoms associated with Huntington's disease, according to a preclinical study. The short-term therapy...

2012-06-21 02:21:23

Single treatment produces long-term improvement in animal models With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models. Researchers suggest the drug therapy, tested in mouse and non-human primate models, could produce sustained...

2012-06-21 02:19:04

A new gene-silencing strategy can reverse core symptoms associated with Huntington's disease, according to a preclinical study published by Cell Press in the June 21st issue of the journal Neuron. The short-term therapy produced sustained benefits in both mouse and primate animal models of this neurodegenerative disorder, which currently lacks an effective treatment. "Our approach is feasible for development now into a therapy for Huntington's disease in man," says senior study author Don...

2012-06-20 19:10:00

Regenerative Medicine Institute research sheds new light on cell death in a common, lethal genetic disease in children, suggesting paths for potential treatment Cedars-Sinai's Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers. The study, published in the June 19 online...

2012-06-19 11:23:40

In Huntington's disease, abnormally long strands of glutamine in the huntingtin (Htt) protein, called polyglutamines, cause subtle changes in cellular functions that lead to neurodegeneration and death. Studies have shown that the activation of the heat shock response, a cellular reaction to stress, doesn't work properly in Huntington's disease. In their research to understand the effects of mutant Htt on the master regulator of the heat shock response, HSF1, researchers have discovered that...

2012-06-19 11:10:05

A new study shows that the compound Coenzyme Q10 (CoQ) reduces oxidative damage, a key finding that hints at its potential to slow the progression of Huntington disease. The discovery, which appears in the inaugural issue of the Journal of Huntington's Disease, also points to a new biomarker that could be used to screen experimental treatments for this and other neurological disorders. "This study supports the hypothesis that CoQ exerts antioxidant effects in patients with Huntington's...


Latest Genetic disorders Reference Libraries

44_b4e6022f2dde476f8bd4cab961972a2d
2007-12-13 19:44:51

The Munchkin is a fairly new breed of cat with a lot of controversy surrounding it. The breed is created by a mutation that causes achondroplasia, or hypochondroplasia, which results in the cats having abnormally short legs. The breed originated when a pregnant, short-legged black cat was discovered in Louisiana in 1983. One of her kittens, a tomcat, became the father of the breeding program for Munchkins. Several cat registries refuse to recognize the breed due to the controversy that...

More Articles (1 articles) »
Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.